Automating Biologics Prior Auth for Specialty Clinics
Klivira streamlines the complex process of biologics prior auth, integrating directly with your EMR to reduce administrative burden and accelerate patient access to critical therapies.
Biologic therapies, including TNF inhibitors and IL-17/23 inhibitors, represent a significant portion of high-cost specialty drug prior authorizations. The intricate requirements for these medications, spanning multiple specialties, frequently lead to workflow bottlenecks and delayed patient care. Klivira addresses these challenges by automating key steps in the biologics prior authorization lifecycle.
The Complexity of Biologics Prior Authorization
Biologic therapies, encompassing drug classes like TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represent a high-volume segment of specialty drug prior authorizations. These medications, critical across rheumatology, gastroenterology, and dermatology, often involve intricate criteria such as indication-specific requirements, step therapy, biosimilar substitution policies, and specific screening documentation. The administrative burden associated with these recurring authorizations can significantly impact revenue cycles and patient access.
Klivira's Automated Workflow for Biologics PA
Klivira provides a comprehensive automation solution designed to streamline the entire biologics prior authorization process. By integrating directly with EMR systems and payer portals, our platform reduces manual touchpoints, accelerates approval times, and improves the predictability of patient access to essential biologic therapies.
Core Automation Capabilities for Biologics Prior Auth
- Indication Classification: Identifies the appropriate specialty and disease state directly from EMR diagnoses.
- Step Therapy Automation: Automatically pulls prior-line therapy history, such as csDMARDs for rheumatology or 5-ASA for IBD, to fulfill payer requirements.
- Biosimilar Substitution Routing: Applies per-payer biosimilar mandates, ensuring adherence to preferred formulary policies.
- Screening Documentation: Extracts and organizes required screening data, including TB (PPD or IGRA), hepatitis B/C, and immunization status, from FHIR data within the EMR.
- Periodic Re-authorization: Manages typical 6/12-month re-authorization cycles, incorporating continuous disease activity and response documentation.
- Medical-vs-Pharmacy Benefit Routing: Intelligently routes authorizations based on the specific administration mode to the correct medical or pharmacy benefit pathway.
Addressing High-Volume Specialty Drug PA Demands
The high volume of specialty pharmacy prior authorizations, in which biologics constitute a meaningful share, is a well-documented challenge in healthcare administration [caqh-index]. Klivira's platform is engineered to manage this scale, minimizing the administrative overhead traditionally associated with these complex, high-cost therapies.
Comprehensive Coverage Across Therapeutic Areas
Klivira supports prior authorization for biologics across a broad spectrum of therapeutic areas, including rheumatology, gastroenterology, dermatology, neurology, pulmonology, hematology, and oncology. Our system is adept at handling diverse drug classes such as TNF inhibitors, IL-17/23 inhibitors, IL-6 inhibitors, and JAK inhibitors.
Seamless EMR Integration and Payer Connectivity
Our platform integrates with leading EMR systems via standards like SMART on FHIR, enabling bidirectional data exchange for efficient prior authorization submission. This connectivity extends to payer portals and utilizes industry standards like X12 278 for electronic prior authorization (ePA), ensuring that all necessary clinical documentation is accurately and securely transmitted.
Frequently asked questions
What specific challenges does biologics prior auth present?
Biologics prior authorization often involves navigating complex requirements, including indication-specific criteria, step therapy mandates, biosimilar substitution policies, and extensive screening documentation. These factors contribute to administrative burden and potential delays in patient access to critical therapies.
How does Klivira automate step therapy for biologics?
Klivira's platform automates step therapy by pulling prior-line therapy history directly from the EMR. For instance, it can verify previous use of csDMARDs for rheumatology or 5-ASA for IBD, ensuring compliance with payer-specific step therapy protocols.
Can Klivira handle biosimilar substitution requirements?
Yes, Klivira applies per-payer biosimilar mandates to streamline the prior authorization process. Our system ensures that biosimilar substitution policies are correctly identified and followed, aligning with payer formulary preferences.
How does Klivira manage re-authorization for chronic biologic therapies?
Klivira supports periodic re-authorization cycles, typically every 6 or 12 months, for chronic biologic treatments. The platform facilitates the collection and submission of continuous disease activity and response documentation required by payers to approve ongoing therapy.
What EMR data does Klivira leverage for biologics PA?
Klivira leverages various EMR data points for biologics prior authorization, including patient diagnoses for indication classification, prior therapy history for step therapy requirements, and FHIR data for essential screening documentation like TB, hepatitis B/C, and immunization status.
Related coverage
Ready to ship this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo